Risk of diabetes in patients treated with HMG-CoA reductase inhibitors

Cho, Yongin; Choe, Eun-Yeong; Lee, Yong-Ho; Seo, Ji Won; Choi, Youn Jeong; Yun, Yujung; Wang, Hye Jin; Ahn, Chul Woo; Soo, Bong; Lee, Hyun Chul; Kang, Eun Seok

doi:10.1016/j.metabol.2014.09.008

Cited by 49 publications

(42 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By including various illnesses and diseases, a risk model of occurrences [19] of cardiovascular disorders [20] can be developed. Moreover, research on recent issues, such as correlations between statins and occurrences of diabetes [21] or cancers [22], can be quickly and easily conducted. Researchers can perform assessments and analyses of economic efficiency [23] regarding statins and comparison analyses of diverse adverse drug effects [24].…”

Section: Discussionmentioning

confidence: 99%

Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research

Kim

Jeong

et al. 2017

Endocrinol Metab

View full text Add to dashboard Cite

BackgroundThe increasing use of electronic medical record (EMR) systems for documenting clinical medical data has led to EMR data being increasingly accessed for clinical trials. In this study, a database of patients who were prescribed statins for the first time was developed using EMR data. A clinical data mart (CDM) was developed for cohort study researchers.MethodsSeoul St. Mary's Hospital implemented a clinical data warehouse (CDW) of data for ~2.8 million patients, 47 million prescription events, and laboratory results for 150 million cases. We developed a research database from a subset of the data on the basis of a study protocol. Data for patients who were prescribed a statin for the first time (between the period from January 1, 2009 to December 31, 2015), including personal data, laboratory data, diagnoses, and medications, were extracted.ResultsWe extracted initial clinical data of statin from a CDW that was established to support clinical studies; the data was refined through a data quality management process. Data for 21,368 patients who were prescribed statins for the first time were extracted. We extracted data every 3 months for a period of 1 year. A total of 17 different statins were extracted. It was found that statins were first prescribed by the endocrinology department in most cases (69%, 14,865/21,368).ConclusionStudy researchers can use our CDM for statins. Our EMR data for statins is useful for investigating the effectiveness of treatments and exploring new information on statins. Using EMR is advantageous for compiling an adequate study cohort in a short period.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research

Kim

Jeong

et al. 2017

Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…In order to investigate whether this risk differs among subjects treated with different statins, Cho et al [15] retrospectively investigated 3680 patients 20 years of age or older without type 2 diabetes or impaired fasting glucose. They started treatment with five different types of HMG-CoA reductase inhibitors for the management of hypercholesterolemia and they were followed up for a mean period of 62.6 months.…”

Section: Effects Of Various Statins On the Development Of New-onset Dmentioning

confidence: 99%

Research advances in metabolism 2015

2016

View full text Add to dashboard Cite

“…The risk of new-onset T2DM during treatment with statins is greater in obese patients and in those with prediabetes [58,59], who also frequently have NAFLD [8][9][10].…”

Section: Accepted Manuscriptmentioning

confidence: 99%